Oragenics, Inc. (LON:0A64)
London · Delayed Price · Currency is GBP · Price in USD 5.13
+1.51 (41.52%)
At close: Jun 2, 2025
Oragenics Company Description
Oragenics, Inc., a development-stage company, engages in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases in the United States.
Its lead product is ONP-002 for the treatment of mild traumatic brain injury, a fully synthetic, non-naturally occurring neurosteroid, which is lipophilic and can cross the blood-brain barrier to reduce swelling, oxidative stress, and inflammation while restoring proper blood flow through gene amplification.
The company also develops NT-CoV2-1, a SARS-CoV-2 vaccine product candidate; and lantibiotics. The company was formerly known as Oragen, Inc. Oragenics, Inc. was incorporated in 1996 and is headquartered in Sarasota, Florida.
Oragenics, Inc.
| Country | United States |
| Founded | 1996 |
| Industry | Biological Products, Except Diagnostic Substances |
| Employees | 5 |
| CEO | Janet Huffman |
Contact Details
Address: 1990 Main Street Sarasota, Florida 34236 United States | |
| Phone | 813 286 7900 |
| Website | oragenics.com |
Stock Details
| Ticker Symbol | 0A64 |
| Exchange | London Stock Exchange |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Janet Huffman | Chief Executive Officer |
| Janet Huffman | Chief Financial Officer |